Abstract
INTRODUCTION: The article presents clinico-radiological examination data of a female patient with a metastatic brain lesion identified four years after a right upper lobectomy for lung adenocarcinoma. The results of dynamic magnetic resonance imaging (several examinations with intervals from three months to one year) from the onset of the first neurological signs, progression of the disease, to the regression of the pathological focus were analyzed. The molecular genetic study revealed deletion in exon 19 of the EGFR gene and mutation of the Т790M gene. Consequently, osimertinib, a third-generation tyrosine kinase inhibitor with a higher ability to penetrate the hematoencephalic barrier than the first and second generations, was initiated.
CONCLUSION: The presented clinical case demonstrated the positive therapeutic effect of osimertinib on a patient with a metastatic brain lesion identified four years after the right upper lobectomy for lung adenocarcinoma, which was confirmed by a reduction of the volume of the metastatic focus and an absence of contrast accumulation via magnetic resonance imaging.